関連する実験動画
Updated: Jan 31, 2026
01:26
Acute Coronary Syndrome V: Nursing Management
Published on: June 19, 2025
325
オプトジェネティクスの多様化と拡張のための分子および細胞アプローチ.
Viviana Gradinaru1,2, Feng Zhang1, Charu Ramakrishnan1
1Department of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Cell
|March 23, 2010
まとめ
新しい光遺傳学的ツールは,精密な細胞制御のために分子取引を活用します. これらの進歩により,より広範なスペクトル制御,強化された阻害力,およびシステム生物学の研究のための多用途の細胞ターゲティングが可能になります.
科学分野:
- 神経科学は神経科学である.
- 分子生物学は分子生物学である.
- バイオテクノロジー バイオテクノロジー
背景:
- オプトジェネティクスは,標的細胞の生物学的プロセスを正確に制御するために光を使用します.
- 既存の光遺傳学的ツールには,スペクトル範囲,効力,および標的の特異性に関する制限があります.
研究 の 目的:
- 分子密輸の原理を用いた光遺傳学的技術の能力を拡大する.
- より広いスペクトルにわたる光学的調節を達成し,阻害力を高めます.
- 遺伝的アイデンティティを超えた,汎用的な細胞標的化戦略を開発する.
主な方法:
- サブセルラーおよびトランスセルラー分子密輸戦略の応用.
- 強化された抑制のためのナノアンペアスケールの塩化物媒介の光電流の開発.
- 細胞形態学と組織トポロジーに基づくターゲティングの実施.
主要な成果:
- 光学調節は,遠赤/赤外線スペクトルと可視範囲に拡張されました.
- 光学阻害の強度の増加は,より高い光力なしで達成されます.
- 遺伝的に処理不可能な生物と未知のプロモーターのために開発された汎用性のある細胞標的化戦略.
結論:
- 分子密輸の原理は,光遺傳学的ツールキットを大幅に拡張します.
- 新しい光遺傳学的ツールは,システム生物学のための拡張された汎用性,効能,ターゲティングを提供します.
- これらの進歩は,健全なシステム生物学と行動研究における光遺傳学的応用を容易にする.
関連する概念動画
Acute Coronary Syndrome V: Nursing Management
325
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
325
Acute Coronary Syndrome IV: Interprofessional Care
288
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
288
Acute Coronary Syndrome III: Diagnostic Studies
268
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
268
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
427
The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
427
Acute Coronary Syndrome I: Introduction
975
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
975
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.3K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.3K